Female Donor Gender is Associated to a Decrease in Post-liver Transplant Survival of Male Recipients Independently to Donor and Recipient Anthropometric Differences

Female Donor Gender is Associated to a Decrease in Post-liver Transplant Survival of Male Recipients Independently to Donor and Recipient Anthropometric Differences | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Female Donor Gender is Associated to a Decrease in Post-liver Transplant Survival of Male Recipients Independently to Donor and Recipient Anthropometric Differences Marcio F. Chedid, Lucas Prediger, Gabriel Lazzarotto-da-Silva, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4824616/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Data on the influence donor gender on post-liver transplant outcomes is scarce / is lacking. The aim of this study was to evaluate the prognostic factors of mortality in patients undergoing liver transplantation (LT) with a thorough evaluation of the influence of the donor variables. Methods Retrospective study of all patients undergoing LT at a single center from December 2011 to December 2018. The main outcome measure of the study was overall patient survival. The mortality predictors were evaluated using Cox regression. Results Overall, 202 patients analyzed in this study, 118 (58.1%) being males, and the average age was 54.19 ± 11.66 years. Post-LT survival for the entire cohort of 202 patients as assessed by the Kaplan-Meier method at 1-, 3-, 5-, and 7 years was 81.6%, 73.1%, 67.6%, and 63%. The only predictor of increased overall mortality was female donor gender [HR = 1.918, IC95%=1.150–3.201, ( p = 0.013)]. Weight and height differences between donor and recipient were not related to mortality ( p = 0.545 for weight and p = 0.964 height). Conclusion Female donor gender was associated with an increase in overall post-LT mortality, especially for male recipients, regardless of anthropometric parameters. For male patients receiving livers from female donors, infection was the most common cause of mortality occurring in the first year following LT. Liver transplantation predictor prognostic survival infection Figures Figure 1 Figure 2 INTRODUCTION Post-liver transplant survival has achieved little improvement over the last decade ( 1 ). Several prognostic factors of mortality after LT have been identified, including donor age, long cold ischemia time, long warm ischemia time, moderate hepatic steatosis in the donor and others ( 2 – 4 ). Data on the influence donor gender on post-liver transplant outcomes is scarce. The aim of this study was to identify the prognostic factors of mortality in patients undergoing LT. PATIENTS AND METHODS All adult patients who underwent a first LT at the authors´ institution from December 2011 to December 2018 were included. Pediatric patients (under 18 years of age), partial graft recipients (split livers and partial grafts from living donors), and patients with concurrent transplants (combined liver and kidney transplant) were not included in this analysis. This study was approved by the local ethics committee. The study researchers signed a confidentiality agreement regarding the use of the collected data. All transplants were performed using the "piggyback" technique. Generally the threshold for performing blood auto transfusion using blood collected by the intraoperative blood recovery device for auto transfusion was 1,000 mL of bleeding (or hemodynamic instability occurrence related to hypovolemia) ( 5 ). Fresh frozen plasma, cryoprecipitate, and platelets were administered as needed according to thromboelastographic evaluation. Abdominal Doppler ultrasound was performed routinely to screen for hepatic vascular complications ( 5 ). Oral feeding was started in the intensive care unit shortly after extubation. Immunosuppression was based on the use of tacrolimus, mycophenolate, and steroids. The study’s primary endpoint was overall post-LT patient survival. The patients were followed until their death or until the end of the study period. Post-LT infectious episodes also were studied and characterized. There were no follow-up losses during the study period. The following variables collected in the immediate pre-transplant period were analyzed: recipient age, gender, ethnicity/race, height, weight, body mass index (BMI), presence of diabetes mellitus (DM), MELD score, hepatitis C virus (HCV) infection, presence of hepatocellular carcinoma (HCC), infection prior to LT, ascites prior to LT, dialysis prior to LT, total bilirubin (TB), international normalized prothrombin time ratio (INR), albumin, sodium, creatinine, platelets, and albumin- bilirubin score (ALBI), donor gender, donor age, donor weight, donor height, recipient weight and recipient height. Data from laboratory tests were collected up to 15 days before LT. Demographic and laboratory data of the donors were also collected and analyzed. For the identification of the prognostic factors related to each of mortality, univariate analysis was performed using the Cox regression method using the variables described above. Variables whose p-value was < .05 in each of the univariate analyses for the outcomes were included in multivariable Cox regressions respective to each outcome. For all analyses, p values ​​< 0.05 were considered statistically significant. Analyzes were performed using SPSS V.18 software. (IBM Corporation, Armonk, New York, U.S.). RESULTS A total of 202 patients who underwent a first LT were included (Table 1 ), of which 118 (58.4%) were male, and the remaining 84 patients (41.6%) were female. The mean age was 54.19 ± 11.66. The predominant ethnicity was Caucasian (94.7% of patients). Eighty-six patients (28.6%) had diabetes mellitus. The main cause of end-stage liver disease was HCV infection, accounting for 125 cases (61.9%). Additionally, HCC in the setting of cirrhosis occurred in 115 patients (56.9%), being the main indication of LT in this cohort. The calculated median MELD score was 13 [IQR = 10–19]. Table 1 Demographic variables of 202 consecutive who underwent liver transplantation at a single center N (%) Mean ± DP Median + Iqr Age 54.19 +- 11.66 57 (Iqr 49.75–62) Male Gender N = 118 (58.4%) Body Mass Index (BMI) 27.76 +- 5.457 27 (Iqr 24–31) MELD Score 16 +- 9 13 (Iqr 10–19) MELD-Na Score 16 +- 8 13 (Iqr 10–19) HCV infection N = 125 (61,9%) Hepatocellular Carcinoma (HCC) N = 115 (56,9%) Albumin 3.18 +- 0.73 3 (Iqr 3–3.5) Bilirubin 4.51 +- 8.4 1,70 (Iqr 0.9–3.22) INR 1. 77 +- 1,58 1,37 (Iqr 1.21 − 1.68) Sodium 139.66 +- 4.13 Creatinine 1.04 +- 0.84 0,8 (Iqr 0.66–1.07) Diabetes N = 86 (28.3%) Post-LT survival for the entire cohort of 202 patients as assessed by the Kaplan-Meier method at 1-, 3-, 5-, and 7 years was 81.6%, 73.1%, 67.6%, and 63%. There were 18 deaths during the first 30 days post-LT days (30-day mortality of 8.9%). Between the 31st and 180th days, there were 7 deaths. Between the 181st and 365th day post-LT, other 13 deaths occurred. Overall, a total of 38 deaths occurred during the first post-LT year for the 202 transplant patients, resulting in a one-year actual survival of 81.1%. During the first 30 post-LT days, the main cause of death was graft dysfunction (n = 12) (either primary or secondary to vascular thrombosis or large-for-size grafts). Among the patients who died during the first 30 post-LT days, 3 suffered from hepatic artery thrombosis, 2 portal vein thrombosis, 4 hemorrhagic shocks. There were 3 abdominal compartment syndromes caused by large-for-size liver grafts. During this period, 5 of the 18 deaths (27.78%) were due to infections. Between the 31st and 180th day post-LT, the main cause of death was infection (six of the seven deaths were caused by infection). Between days 181 and 365 post-LT, infection was also the main cause of death (eight of the thirteen deaths in this period were caused by infection). Table 2 a presents the results of univariate analysis by Cox regression with the outcome of mortality occurring throughout the study follow-up. According to this analysis, female donor gender (HR = 1.806, [95%CI = 1.091–2.988]; p = 0.021) was the only predictor of overall post-LT mortality. Table 2 Univariate analysis of the factors to the outcome overall death (entire post-transplant follow-up) of 202 consecutive patients who underwent liver transplantation at a single center Hazard Ratio [IC 95%] p-Value Age 0.996[0.976–1.016] 0.677 Female Gender 0.830[0.511–1.348] 0.451 Receptor Height 1.002 [0.978–1.026] 0.884 Receptor Weight 1.006 [0.990–1.023] 0.468 Body Mass Index (BMI) 1.026[0.973–1.080] 0.342 Diabetes 1.367[0.836–2.237] 0.213 MELD Score 1.003[0.977–1.031] 0.811 MELD-Na Socre 1.003[0.977–1.030] 0.840 HCV Infection 0.912[0.563–1.477] 0.708 Hepatocelular Carcinoma (HCC) 1.003[0.623–1.614] 0.991 Total Bilirubin 1.011[0.986–1.037] 0.389 INR 0.886[0.702–1.118] 0.309 Sodium 1.008[0.951–1.068] 0.788 Creatinine 0.828[0.573–1.196] 0.314 Platelets/20,000 1.022[0.960–1.088] 0.501 Albumin 0.749[0.546–1.027] 0.072 Albumin–Bilirubina Grade (ALBI) 2 – categories grade 1/grade 2 ref (≤ -1.39) grade 3 (>-1.39) 1.155[0.668–1.995] 0.606 Pre-Transplant Dyalisis 1.124[0.486–2.598] 0.785 Infection Prior to LT 1.301[0.744–2.275] 0.355 Ascites Prior to LT 1.405[0.876–2.253] 0.158 Donor Infection 0.956[0.550–1.644] 0.875 Donor Age 1.011[0.996–1.027] 0.154 Donor Gender, Female 1.806[1.091–2.988] 0.021 Donor BMI 0.988[0.914–1.069] 0.771 Donor Height 0.696 [0.037–13.192] 0.809 Donor Weight 0.996 [0.976–1.016] 0.669 Height Difference between Donor and Recipient 1.000[0.980–1.021] 0.964 Weight Difference between Donor and Recipient 0.996[0.982–1.010] 0.545 Infection, Receptor During Transplant Hospitalization 0.793[0.468–1.345] 0.390 Infection During First 90 Post-Transplant Days 0.646[0.403–1.035] 0.069 Infection During First Year 0.689[0.430–1.104] 0.121 Anthropometric parameters of donor and recipient also were studied. The difference of donor and recipient weight was not related to a decreased post-LT survival ( p = 0.545). Likewise, the difference of donor and recipient height was not related to a decreased post-LT survival ( p = 0.964). Figure 1a demonstrates the analysis of post-transplant survival using the Kaplan-Meier method, stratified by donor gender. Post-LT survival for patients who received a liver graft from a male donor method at 1, 3, 5, and 7 years was 86.3%, 79.1%, 73.8%, and 71 .8% versus 77.4%, 64.9%, 59.6%, 54.2% for patients who received liver from a female donor (p = 0.013). Figure 1b depicts the analysis of post-transplant survival stratified by recipient gender. Post-LT survival for male recipients was not different from that of female recipients ( p = 0.45). Figure 2 shows recipient survival stratified in four groups by donor and recipient gender. The highest survival occurred for male patients receiving a liver from a male donor (1 year = 85.7%, 3 years = 80.1%, 5 years = 73.1% and 7 years = 73.1%), whereas the lowest survival occurred for male patients receiving a liver graft from female donors (1 year = 75%, 3 years = 68.5%, 5 years = 60.8% and 7 years = 52.6%) ( p = 0.028). Analyzing only male gender recipients, receiving a liver from a female gender donor as compared with receiving a liver from a male donor was associated with an increase of 2.26 times in overall post-LT mortality (95%CI = 1.149–4.315, p = 0.018). No statistically sigificant survival difference was detected for the comparisons between all the other donor-recipient gender comparisons [female donor to female recipient vs. male donor to male recipient, p = 0.213), (female donor to female recipient vs. female donor to male recipient, p = 0.466), (female donor to female recipient vs. male donor to female recipient, p = 0.513), (male donor to male recipient vs. male donor to female recipient, p = 0.689), (female donor to male recipient vs. male donor to female recipient, p = 0.12)]. Additional analyses were performed in the group that had the lowest overall survival (male recipients receiving livers from female donors). Among that subgroup of patients, the difference of donor and recipient weight was not related to a decreased post-LT survival ( p = 0.425). Likewise, the difference between donor and recipient height was not related to a decreased post-LT survival ( p = 0.114). As an attempt to quantify the weight mismatches between donor and recipients, we calculated the difference between the weight of the donor and that of the recipient (donor weight – recipient). Thus, we have grouped the donor-to-recipient weight differences into three groups. First group included individuals with donor-recipient weight differences of more than 10 Kg (recipient weighted 10 or more kilos than the donor); for the second group donor-recipient weight difference was between − 10 and + 10 Kg; third group had a donor-recipient weight differences of more than 10 kg (recipient weighted 10 or less kilos than the donor). Post-LT survival for the three groups was not statistically different ( p = 0.399). In order to quantify the Height mismatches between donor and recipients, we calculated the difference between the height of the donor and that of the recipient (donor height – recipient). For quantifying the height differences between the donor and the recipient, we also grouped the height differences into three groups. The first group encompassed individuals with donor-recipient height differences of less than 10 cm (recipient was 10 or more centimeters taller than the donor); for the second group, donor- recipient height differences were between − 10 and + 10 cm; third group had patients with donor weight-recipient height differences 10 or more kilograms (recipient was 10 or more centimeters shorter than the donor). Post-LT survival for the three groups was not statistically different ( p = 0.772). Among the group of 46 male patients receiving livers from female donors, 12 deaths occurred during the first year (mortality rate of 26.1%) as compared to a 14% 1-year mortality of male recipients who received livers from male donors. Death causes of the 12 male recipients who received livers from female donors were: infection (n = 7, 58.3%), hemorrhagic shock (n = 1), hepatic artery thrombosis (n = 1), portal vein thrombosis (n = 1), unknown (n = 2). In contrast, in the group of male patients who received liver allografts from male donors, only 12.5% of the deaths occurring during the first post-LT year were caused by infection DISCUSSION In the present study, the outcomes of 202 consecutive adult patients undergoing LT at a single center are analyzed. The main cause of end-stage liver disease in this cohort was cirrhosis secondary to HCV infection, which occurred in 125 out of 202 cases (61.9%). The main indication to LT was HCV cirrhosis with or without HCC. Post-LT survival at 1, 3, 5 and 7 years was within international parameters ( 6 – 8 ), being comparable to that of other international centers ( 9 ). Among all parameters studied, female donor gender was the only predictor of post-LT mortality, being associated with an increase of 81.6% in overall post-LT mortality. Remarkably, the association of female donor gender to post-LT recipient mortality was detected in both male and female recipients. Moreover, this association of female donor gender and mortality was stronger for male recipients. Thus, male recipients who received LT from female donors experienced 2.2 times increase in overall mortality as compared to male recipients who received livers from male donors (12% higher mortality at 5 years and 21% higher at 7 years post-LT). Notably, neither weight nor height incompatibilities was related to inferior outcomes in this cohort. Thus, this is the first study showing that the deleterious association of female liver donors - male recipients is not related either to weight or to height incompatibility between donor and recipient. The few available literature studies on the subject exhibiting conflict results ( 6 – 15 ). While some studies ( 6 – 7 , 11 , 13 – 15 ) revealed that liver from female donors pose to an increased risk of death, other studies do not share the same results ( 8 – 10 , 12 ). A recent systematic review and meta-analysis showed that female donors in male recipients was associated to an 83% decrease in post-LT survival ( 16 ). To date, the reason for this inferior survival for male receiving livers from female donors has not been elucidated. Although some authors postulate that it may be related to different sizes among human males and females (a small-for-size effect) ( 16 ), the present study did not detect any association of weight and height mismatch to a decrease in overall post-LT survival. Moreover, even in the group of male recipients who received a liver from female donors, neither weight nor height differences accounted for any increase in mortality. As an attempt to elucidate the reasons for death of males receiving livers from female donors, a search for the reasons for graft failures was carried out. Interestingly, 58% of all first year mortality in this group was caused by infection. In contrast, infection was responsible for only 12.5% of all first year deaths of males who received livers from male donors. Post-transplant infection was not a predictor of mortality in this study. However, infection was associated with a significant increase in post-transplant hospital stay. It is possible that greater rigor in immunosuppression could prevent the occurrence of infection in patients undergoing LT, positively impacting the long-term survival. The most common site for infection in our series was sepsis without a defined infectious site, with a total of 20 episodes (31.8%). The abdomen, the most common site of infection in literature studies, was only the third most common site of infection in the present study (20.6% of cases). These data differ in relation to two recent review articles, which establish the abdomen as the most common site of infection in LT recipients ( 17 – 18 ). The present study has some limitations. The main one is the retrospective design. The nature of retrospective studies increases the chance of measurement biases. The absence of randomization is another limitation. However, it would be impossible to randomize LT patients to receive a liver graft from a specific deceased donor gender. In summary, female donor gender was associated to an increase in overall post-LT mortality, especially for male recipients. The reason for those inferior outcomes of male receiving livers from female donors was not related to anthropometric differences. For male patients receiving livers from female donors, infection was the most common cause of mortality occurring in the first year following LT. Thus, future studies are needed to elucidate whether immune discrepancies would be accountable for increased mortality of males receiving livers from female donors. Abbreviations ALBI – Albumin-Bilirubin score AR – Acute rejection during the first post-transplant year HCC – Hepatocellular carcinoma MELD - Model for End-Stage Liver Disease LT – Liver Transplantation Post-LT – Post-Liver transplantation HCV– Hepatitis C virus Declarations COMPETING INTERESTS: The authors have no conflicts of interest to disclose. This study was supported by the Hospital de Clinicas de Porto Alegre Research Incentive Fund (FIPE/HCPA, grant number 2017-0271). RESEARCH INVOLVING HUMAN PARTICIPANTS (ETHICAL APPROVAL): This study complies with ethical standards and was approved by the Hospital de Clínicas de Porto Alegre Institutional Review Board ( Grupo de Pesquisa e Pós-Graduação—GPPG HCPA ). (2017-0271) All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was waived by the ethics committee because this is an observational retrospective study. AUTHOR’S CONTRIBUTIONS: M.F.C- Study conception and design, acquisition of data, analysis and interpretation of data, critical revision of manuscript. L.P. - Study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript. G.L.S - Analysis and interpretation of data, drafting of manuscript. J.C. - Acquisition of data, critical revision of manuscript. N.Z. - Acquisition of data, critical revision of manuscript. A.A. - Study conception and design, critical revision of manuscript. R.M. - Study conception and design, critical revision of manuscript. T.J.M.G.F - Study conception and design, critical revision of manuscript. L.Z.G. - Study conception and design, analysis and interpretation of data, drafting of manuscript. References Rana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H, et al. No Gains in Long-Term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg . 2018. Adam R, Sanchez C, Astarcioglu I, Bismuth H. (1995) Deleterious effect of extended cold ischemia time on the posttransplant outcome of aged livers. Transplant Proc 27:1181-1183. Deschenes M, Forbes C, Tchervenkov J, Barkun J, Metrakos P, Tector J, et al. (1999) Use of older donor livers is associated with more extensive ischemic damage on intraoperative biopsies during liver transplantation. Liver Transpl Surg 5:357-361. Chedid MF, Rosen CB, Nyberg SL, Heimbach JK. Excellent long-term patient and graft survival are possible with the use of livers from deceased septuagenarian and octogenarian donors. HPB (Oxford) 2014; 16: 852-8. Bernardi N, Chedid MF, Grezzana-Filho TMJ, Chedid AD, Pinto MA, Leipnitz, et al. Pre-transplant ALBI grade 3 is associated with increased mortality after liver transplantation, Dig Dis Sci 2019; 1695-1704. Pinto MA, Grezzana-Filho TJM, Chedid AD, Leipnitz I, Prediger JE, Alvares-da-Silva MR, de Araújo A, Zahler S, Lopes BB, Giampaoli AZD, Kruel CRP, Chedid MF. Impact of intraoperative blood salvage and autologous transfusion during liver transplantation for hepatocellular carcinoma. Langenbecks Arch Surg . 2021;406:67-74. Kahn D, Gavaler JS, Makowka L, van Thiel DH. Gender of donor influences outcome after orthotopic liver transplantation in adults . Dig Dis Sci 1993; 38: 1485-1488. Marino IR, Doyle HR, Aldrighetti L, Doria C, McMichael J, Gayowski T, Fung JJ, Tzakis AG, Starzl TE. Effect of donor age and sex on the outcome of liver transplantation. Hepatology 1995; 22: 1754-1762. Grande L, Rull A, Rimola A, Manyalic M, Cabrer C, Garcia-Valdecasas JC, Navasa M, Fuster J, Lacy AM, González FX, López-Boado MA, Visa J. Impact of donor gender on graft survival after liver transplantation. Transplant Proc 1997; 29: 3373-3374. Berrevoet F, Hesse UJ, de Laere S, Jacobs B, Pattyn P, de Hemptinne B. Impact of donor and recipient gender on liver transplantation. Transplant Proc 1997; 29: 3431-3432. Brooks BK, Levy MF, Jennings LW, Abbasoglu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Influence of donor and recipient gender on the outcome of liver transplantation. Transplant Proc 1997; 29: 475-476. Croome KP, Segal D, Hernandez-Alejandro R, Adams PC, Thomson A, Chandok N. Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants. J Hepatobiliary Pancreat Sci 2014; 21: 269-274. Grąt M, Lewandowski Z, Patkowski W, Wronka KM, Grąt K, Krasnodębski M, Ligocka J, Zborowska H, Krawczyk M. Relevance of male-to-female sex mismatch in liver transplantation for primary biliary cirrhosis. Ann Transplant 2015; 20: 116-123. Schoening WN, Helbig M, Buescher N, Andreou A, Bahra M, Schmitz V, Pascher A, Pratschke J, Seehofer D. Gender Matches in Liver Transplant Allocation: Matched and Mismatched Male-Female Donor-Recipient Combinations; Long-term Follow-up of More Than 2000 Patients at a Single Center. Exp Clin Transplant. 2016 Apr;14(2):184-90. PMID: 27015533. Yoshizumi T, Shirabe K, Taketomi A, Uchiyama H, Harada N, Ijichi H, Yoshimatsu M, Ikegami T, Soejima Y, Maehara Y. Risk factors that increase mortality after living donor liver transplantation. Transplantation. 2012 Jan 15;93(1):93-8. doi: 10.1097/TP.0b013e318238dacd. PMID: 22203391. Lai JC, Feng S, Roberts JP, Terrault NA. Gender differences in liver donor quality are predictive of graft loss. Am J Transplant. 2011 Feb;11(2):296-302. doi: 10.1111/j.1600-6143.2010.03385.x. Epub 2011 Jan 10. PMID: 21219572; PMCID: PMC3076602. Lai Q, Giovanardi F, Melandro F, Larghi Laureiro Z, Merli M, Lattanzi B, Hassan R, Rossi M, Mennini G. Donor-to-recipient gender match in liver transplantation: A systematic review and meta-analysis. World J Gastroenterol , 2018; 28;24(20):2203-2210. Green M. Introduction: Infections in solid organ transplantation. Am J Transplant . 2013;13 Suppl 4:3-8. Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Virulence . 2016;7:329-40. Maciel NB, Schwambach KH, Blatt CR. Liver Transplantation: Tacrolimus Blood Levels Variation and Survival, Rejection and Death Outcomes. Arq Gastroenterol.2021;58:370-376. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4824616","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":337839420,"identity":"81308f48-e968-452a-8e0e-b1bd41ae0f78","order_by":0,"name":"Marcio F. Chedid","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA00lEQVRIiWNgGAWjYFACHiAyYJYzgPCYGRgkiNRiTKoWBubEDURr0W0/e/DBmwLr9O3sZw9+YKiwTmyQ7n2AV4vZmbxkwzkG6bk7e/KSJRjOpCc2yBw3wK/lBo+ZNI/B4dwNN3gMJBjbDic2SKThdxhQi/lvoJZ0gxs8xj8Y/xGnxYwZqCUBqMVMgrGBGC1ncowlgX4x3HAmL80i4Vi6cZvMMQJajp8x/PDmj7W8wfGzh298qLGW7Zduw68FCQAjKAFIsRGtAaxlFIyCUTAKRgE2AAAPBkMmrdaeDgAAAABJRU5ErkJggg==","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":true,"prefix":"","firstName":"Marcio","middleName":"F.","lastName":"Chedid","suffix":""},{"id":337839421,"identity":"965fab99-dfcf-4348-a782-7f783c2e42ac","order_by":1,"name":"Lucas Prediger","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Lucas","middleName":"","lastName":"Prediger","suffix":""},{"id":337839423,"identity":"f7f43023-4e1b-4fd1-ad06-2e6a49b02d1c","order_by":2,"name":"Gabriel Lazzarotto-da-Silva","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Gabriel","middleName":"","lastName":"Lazzarotto-da-Silva","suffix":""},{"id":337839424,"identity":"42db13f8-84b6-4d8f-b09c-70cfd4d216f3","order_by":3,"name":"Jane Cronst","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Jane","middleName":"","lastName":"Cronst","suffix":""},{"id":337839425,"identity":"ca2fd377-64af-4edf-ad9b-57e052095d45","order_by":4,"name":"Nathalia Zarichta","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Nathalia","middleName":"","lastName":"Zarichta","suffix":""},{"id":337839427,"identity":"b96c863d-2b0f-47bf-89d6-027c626c0a10","order_by":5,"name":"Alexandre Araujo","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Alexandre","middleName":"","lastName":"Araujo","suffix":""},{"id":337839428,"identity":"ae9cea89-0787-49eb-b4e9-100b940a3bc9","order_by":6,"name":"Roberta Marchiori","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Roberta","middleName":"","lastName":"Marchiori","suffix":""},{"id":337839430,"identity":"a831f1e6-3d5a-4a17-8a26-64bf86a4f432","order_by":7,"name":"Tomaz J. M. Grezzana-Filho","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Tomaz","middleName":"J. M.","lastName":"Grezzana-Filho","suffix":""},{"id":337839432,"identity":"f82c1c57-9bc9-4081-8d91-e5cf9a9b2457","order_by":8,"name":"Luciano Z. Goldani","email":"","orcid":"","institution":"Hospital de Clínicas de Porto Alegre","correspondingAuthor":false,"prefix":"","firstName":"Luciano","middleName":"Z.","lastName":"Goldani","suffix":""}],"badges":[],"createdAt":"2024-07-29 23:01:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4824616/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4824616/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":63914204,"identity":"ef288e9c-1629-4a66-b448-88cc116fe25a","added_by":"auto","created_at":"2024-09-03 17:07:37","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":318050,"visible":true,"origin":"","legend":"\u003cp\u003eSee image above for figure legend.\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"FIG1ARTIGODONORGENDERFINALFEB192024.png","url":"https://assets-eu.researchsquare.com/files/rs-4824616/v1/f637444d4f69c8bd6d480153.png"},{"id":63914203,"identity":"4ed511a7-a151-44bd-ae2a-61660b22eaef","added_by":"auto","created_at":"2024-09-03 17:07:37","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":103645,"visible":true,"origin":"","legend":"\u003cp\u003eSee image above for figure legend.\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"FIG2ARTIGODONORGENDERFINALFEB192024.png","url":"https://assets-eu.researchsquare.com/files/rs-4824616/v1/b1dd0353aca3704a05efe15f.png"},{"id":63915288,"identity":"99daee4a-6afb-4ad5-b4c7-aad504784343","added_by":"auto","created_at":"2024-09-03 17:23:39","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1000465,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4824616/v1/52a25945-2686-4881-8a34-1747ea2e7a32.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eFemale Donor Gender is Associated to a Decrease in Post-liver Transplant Survival of Male Recipients Independently to Donor and Recipient Anthropometric Differences\u003c/p\u003e","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003ePost-liver transplant survival has achieved little improvement over the last decade (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Several prognostic factors of mortality after LT have been identified, including donor age, long cold ischemia time, long warm ischemia time, moderate hepatic steatosis in the donor and others (\u003cspan additionalcitationids=\"CR3\" citationid=\"CR3\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eData on the influence donor gender on post-liver transplant outcomes is scarce. The aim of this study was to identify the prognostic factors of mortality in patients undergoing LT.\u003c/p\u003e"},{"header":"PATIENTS AND METHODS","content":"\u003cp\u003eAll adult patients who underwent a first LT at the authors\u0026acute; institution from December 2011 to December 2018 were included. Pediatric patients (under 18 years of age), partial graft recipients (split livers and partial grafts from living donors), and patients with concurrent transplants (combined liver and kidney transplant) were not included in this analysis. This study was approved by the local ethics committee. The study researchers signed a confidentiality agreement regarding the use of the collected data.\u003c/p\u003e \u003cp\u003eAll transplants were performed using the \"piggyback\" technique. Generally the threshold for performing blood auto transfusion using blood collected by the intraoperative blood recovery device for auto transfusion was 1,000 mL of bleeding (or hemodynamic instability occurrence related to hypovolemia) (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Fresh frozen plasma, cryoprecipitate, and platelets were administered as needed according to thromboelastographic evaluation.\u003c/p\u003e \u003cp\u003eAbdominal Doppler ultrasound was performed routinely to screen for hepatic vascular complications (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Oral feeding was started in the intensive care unit shortly after extubation. Immunosuppression was based on the use of tacrolimus, mycophenolate, and steroids.\u003c/p\u003e \u003cp\u003eThe study\u0026rsquo;s primary endpoint was overall post-LT patient survival. The patients were followed until their death or until the end of the study period. Post-LT infectious episodes also were studied and characterized. There were no follow-up losses during the study period.\u003c/p\u003e \u003cp\u003eThe following variables collected in the immediate pre-transplant period were analyzed: recipient age, gender, ethnicity/race, height, weight, body mass index (BMI), presence of diabetes mellitus (DM), MELD score, hepatitis C virus (HCV) infection, presence of hepatocellular carcinoma (HCC), infection prior to LT, ascites prior to LT, dialysis prior to LT, total bilirubin (TB), international normalized prothrombin time ratio (INR), albumin, sodium, creatinine, platelets, and albumin- bilirubin score (ALBI), donor gender, donor age, donor weight, donor height, recipient weight and recipient height. Data from laboratory tests were collected up to 15 days before LT. Demographic and laboratory data of the donors were also collected and analyzed.\u003c/p\u003e \u003cp\u003eFor the identification of the prognostic factors related to each of mortality, univariate analysis was performed using the Cox regression method using the variables described above. Variables whose p-value was \u0026lt;\u0026thinsp;.05 in each of the univariate analyses for the outcomes were included in multivariable Cox regressions respective to each outcome. For all analyses, \u003cem\u003ep\u003c/em\u003e values ​​\u0026lt; 0.05 were considered statistically significant. Analyzes were performed using SPSS V.18 software. (IBM Corporation, Armonk, New York, U.S.).\u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003eA total of 202 patients who underwent a first LT were included (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), of which 118 (58.4%) were male, and the remaining 84 patients (41.6%) were female. The mean age was 54.19\u0026thinsp;\u0026plusmn;\u0026thinsp;11.66. The predominant ethnicity was Caucasian (94.7% of patients). Eighty-six patients (28.6%) had diabetes mellitus. The main cause of end-stage liver disease was HCV infection, accounting for 125 cases (61.9%). Additionally, HCC in the setting of cirrhosis occurred in 115 patients (56.9%), being the main indication of LT in this cohort. The calculated median MELD score was 13 [IQR\u0026thinsp;=\u0026thinsp;10\u0026ndash;19].\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDemographic variables of 202 consecutive who underwent liver transplantation at a single center\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026minus;\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMean\u0026thinsp;\u0026plusmn;\u0026thinsp;DP\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMedian\u0026thinsp;+\u0026thinsp;Iqr\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAge\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e54.19 +- 11.66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57 (Iqr 49.75\u0026ndash;62)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMale Gender\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;118 (58.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBody Mass Index (BMI)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e27.76 +- 5.457\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e27 (Iqr 24\u0026ndash;31)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMELD Score\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e16 +- 9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13 (Iqr 10\u0026ndash;19)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMELD-Na Score\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e16 +- 8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13 (Iqr 10\u0026ndash;19)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHCV infection\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;125 (61,9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHepatocellular Carcinoma (HCC)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;115 (56,9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAlbumin\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e3.18 +- 0.73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (Iqr 3\u0026ndash;3.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBilirubin\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e4.51 +- 8.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1,70 (Iqr 0.9\u0026ndash;3.22)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eINR\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e1. 77 +- 1,58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1,37 (Iqr 1.21 \u0026minus;\u0026thinsp;1.68)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSodium\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e139.66 +- 4.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCreatinine\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026minus;\" colname=\"c3\"\u003e \u003cp\u003e1.04 +- 0.84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0,8 (Iqr 0.66\u0026ndash;1.07)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDiabetes\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;86 (28.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003ePost-LT survival for the entire cohort of 202 patients as assessed by the Kaplan-Meier method at 1-, 3-, 5-, and 7 years was 81.6%, 73.1%, 67.6%, and 63%. There were 18 deaths during the first 30 days post-LT days (30-day mortality of 8.9%). Between the 31st and 180th days, there were 7 deaths. Between the 181st and 365th day post-LT, other 13 deaths occurred. Overall, a total of 38 deaths occurred during the first post-LT year for the 202 transplant patients, resulting in a one-year actual survival of 81.1%.\u003c/p\u003e \u003cp\u003eDuring the first 30 post-LT days, the main cause of death was graft dysfunction (n\u0026thinsp;=\u0026thinsp;12) (either primary or secondary to vascular thrombosis or large-for-size grafts). Among the patients who died during the first 30 post-LT days, 3 suffered from hepatic artery thrombosis, 2 portal vein thrombosis, 4 hemorrhagic shocks. There were 3 abdominal compartment syndromes caused by large-for-size liver grafts. During this period, 5 of the 18 deaths (27.78%) were due to infections.\u003c/p\u003e \u003cp\u003eBetween the 31st and 180th day post-LT, the main cause of death was infection (six of the seven deaths were caused by infection). Between days 181 and 365 post-LT, infection was also the main cause of death (eight of the thirteen deaths in this period were caused by infection).\u003c/p\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea presents the results of univariate analysis by Cox regression with the outcome of mortality occurring throughout the study follow-up. According to this analysis, female donor gender (HR\u0026thinsp;=\u0026thinsp;1.806, [95%CI\u0026thinsp;=\u0026thinsp;1.091\u0026ndash;2.988]; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.021) was the only predictor of overall post-LT mortality.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eUnivariate analysis of the factors to the outcome overall death (entire post-transplant follow-up) of 202 consecutive patients who underwent liver transplantation at a single center\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHazard Ratio [IC 95%]\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003ep-Value\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAge\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.996[0.976\u0026ndash;1.016]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.677\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eFemale Gender\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.830[0.511\u0026ndash;1.348]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.451\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eReceptor Height\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.002 [0.978\u0026ndash;1.026]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.884\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eReceptor Weight\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.006 [0.990\u0026ndash;1.023]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.468\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBody Mass Index (BMI)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.026[0.973\u0026ndash;1.080]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.342\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDiabetes\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.367[0.836\u0026ndash;2.237]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.213\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMELD Score\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.003[0.977\u0026ndash;1.031]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.811\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eMELD-Na Socre\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.003[0.977\u0026ndash;1.030]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.840\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHCV Infection\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.912[0.563\u0026ndash;1.477]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.708\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHepatocelular Carcinoma (HCC)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.003[0.623\u0026ndash;1.614]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.991\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTotal Bilirubin\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.011[0.986\u0026ndash;1.037]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.389\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eINR\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.886[0.702\u0026ndash;1.118]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.309\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSodium\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.008[0.951\u0026ndash;1.068]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.788\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCreatinine\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.828[0.573\u0026ndash;1.196]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.314\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePlatelets/20,000\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.022[0.960\u0026ndash;1.088]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.501\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAlbumin\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.749[0.546\u0026ndash;1.027]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.072\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAlbumin\u0026ndash;Bilirubina Grade (ALBI) 2 \u0026ndash; categories\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003egrade 1/grade 2 ref (\u0026le; -1.39)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cb\u003egrade 3 (\u0026gt;-1.39)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.155[0.668\u0026ndash;1.995]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.606\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePre-Transplant Dyalisis\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.124[0.486\u0026ndash;2.598]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.785\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfection Prior to LT\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.301[0.744\u0026ndash;2.275]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.355\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAscites Prior to LT\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.405[0.876\u0026ndash;2.253]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.158\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDonor Infection\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.956[0.550\u0026ndash;1.644]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.875\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDonor Age\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.011[0.996\u0026ndash;1.027]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.154\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003eDonor Gender, Female\u003c/span\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e\u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003e1.806[1.091\u0026ndash;2.988]\u003c/span\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003e0.021\u003c/span\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDonor BMI\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.988[0.914\u0026ndash;1.069]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.771\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDonor Height\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.696 [0.037\u0026ndash;13.192]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.809\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDonor Weight\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.996 [0.976\u0026ndash;1.016]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.669\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHeight Difference between Donor and Recipient\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1.000[0.980\u0026ndash;1.021]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.964\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eWeight Difference between Donor and Recipient\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.996[0.982\u0026ndash;1.010]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.545\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfection, Receptor During Transplant Hospitalization\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.793[0.468\u0026ndash;1.345]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.390\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfection During First 90 Post-Transplant Days\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.646[0.403\u0026ndash;1.035]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.069\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfection During First Year\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.689[0.430\u0026ndash;1.104]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.121\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAnthropometric parameters of donor and recipient also were studied. The difference of donor and recipient weight was not related to a decreased post-LT survival (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.545). Likewise, the difference of donor and recipient height was not related to a decreased post-LT survival (\u003cem\u003ep\u0026thinsp;=\u003c/em\u003e\u0026thinsp;0.964).\u003c/p\u003e \u003cp\u003eFigure 1a demonstrates the analysis of post-transplant survival using the Kaplan-Meier method, stratified by donor gender. Post-LT survival for patients who received a liver graft from a male donor method at 1, 3, 5, and 7 years was 86.3%, 79.1%, 73.8%, and 71 .8% \u003cem\u003eversus\u003c/em\u003e 77.4%, 64.9%, 59.6%, 54.2% for patients who received liver from a female donor (p\u0026thinsp;=\u0026thinsp;0.013).\u003c/p\u003e \u003cp\u003eFigure 1b depicts the analysis of post-transplant survival stratified by recipient gender. Post-LT survival for male recipients was not different from that of female recipients (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.45).\u003c/p\u003e \u003cp\u003eFigure 2 shows recipient survival stratified in four groups by donor and recipient gender. The highest survival occurred for male patients receiving a liver from a male donor (1 year\u0026thinsp;=\u0026thinsp;85.7%, 3 years\u0026thinsp;=\u0026thinsp;80.1%, 5 years\u0026thinsp;=\u0026thinsp;73.1% and 7 years\u0026thinsp;=\u0026thinsp;73.1%), whereas the lowest survival occurred for male patients receiving a liver graft from female donors (1 year\u0026thinsp;=\u0026thinsp;75%, 3 years\u0026thinsp;=\u0026thinsp;68.5%, 5 years\u0026thinsp;=\u0026thinsp;60.8% and 7 years\u0026thinsp;=\u0026thinsp;52.6%) (\u003cem\u003ep\u0026thinsp;=\u003c/em\u003e\u0026thinsp;0.028). Analyzing only male gender recipients, receiving a liver from a female gender donor as compared with receiving a liver from a male donor was associated with an increase of 2.26 times in overall post-LT mortality (95%CI\u0026thinsp;=\u0026thinsp;1.149\u0026ndash;4.315, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.018).\u003c/p\u003e \u003cp\u003eNo statistically sigificant survival difference was detected for the comparisons between all the other donor-recipient gender comparisons [female donor to female recipient \u003cem\u003evs.\u003c/em\u003e male donor to male recipient, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.213), (female donor to female recipient \u003cem\u003evs.\u003c/em\u003e female donor to male recipient, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.466), (female donor to female recipient \u003cem\u003evs.\u003c/em\u003e male donor to female recipient, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.513), (male donor to male recipient \u003cem\u003evs.\u003c/em\u003e male donor to female recipient, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.689), (female donor to male recipient \u003cem\u003evs.\u003c/em\u003e male donor to female recipient, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.12)].\u003c/p\u003e \u003cp\u003eAdditional analyses were performed in the group that had the lowest overall survival (male recipients receiving livers from female donors). Among that subgroup of patients, the difference of donor and recipient weight was not related to a decreased post-LT survival (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.425). Likewise, the difference between donor and recipient height was not related to a decreased post-LT survival (\u003cem\u003ep\u0026thinsp;=\u003c/em\u003e\u0026thinsp;0.114).\u003c/p\u003e \u003cp\u003eAs an attempt to quantify the weight mismatches between donor and recipients, we calculated the difference between the weight of the donor and that of the recipient (donor weight \u0026ndash; recipient). Thus, we have grouped the donor-to-recipient weight differences into three groups. First group included individuals with donor-recipient weight differences of more than 10 Kg (recipient weighted 10 or more kilos than the donor); for the second group donor-recipient weight difference was between \u0026minus;\u0026thinsp;10 and +\u0026thinsp;10 Kg; third group had a donor-recipient weight differences of more than 10 kg (recipient weighted 10 or less kilos than the donor). Post-LT survival for the three groups was not statistically different (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.399).\u003c/p\u003e \u003cp\u003eIn order to quantify the Height mismatches between donor and recipients, we calculated the difference between the height of the donor and that of the recipient (donor height \u0026ndash; recipient). For quantifying the height differences between the donor and the recipient, we also grouped the height differences into three groups. The first group encompassed individuals with donor-recipient height differences of less than 10 cm (recipient was 10 or more centimeters taller than the donor); for the second group, donor- recipient height differences were between \u0026minus;\u0026thinsp;10 and +\u0026thinsp;10 cm; third group had patients with donor weight-recipient height differences 10 or more kilograms (recipient was 10 or more centimeters shorter than the donor). Post-LT survival for the three groups was not statistically different (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.772).\u003c/p\u003e \u003cp\u003eAmong the group of 46 male patients receiving livers from female donors, 12 deaths occurred during the first year (mortality rate of 26.1%) as compared to a 14% 1-year mortality of male recipients who received livers from male donors. Death causes of the 12 male recipients who received livers from female donors were: infection (n\u0026thinsp;=\u0026thinsp;7, 58.3%), hemorrhagic shock (n\u0026thinsp;=\u0026thinsp;1), hepatic artery thrombosis (n\u0026thinsp;=\u0026thinsp;1), portal vein thrombosis (n\u0026thinsp;=\u0026thinsp;1), unknown (n\u0026thinsp;=\u0026thinsp;2). In contrast, in the group of male patients who received liver allografts from male donors, only 12.5% of the deaths occurring during the first post-LT year were caused by infection\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eIn the present study, the outcomes of 202 consecutive adult patients undergoing LT at a single center are analyzed. The main cause of end-stage liver disease in this cohort was cirrhosis secondary to HCV infection, which occurred in 125 out of 202 cases (61.9%). The main indication to LT was HCV cirrhosis with or without HCC. Post-LT survival at 1, 3, 5 and 7 years was within international parameters (\u003cspan additionalcitationids=\"CR7\" citationid=\"CR7\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e8\u003c/span\u003e), being comparable to that of other international centers (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e9\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eAmong all parameters studied, female donor gender was the only predictor of post-LT mortality, being associated with an increase of 81.6% in overall post-LT mortality. Remarkably, the association of female donor gender to post-LT recipient mortality was detected in both male and female recipients. Moreover, this association of female donor gender and mortality was stronger for male recipients. Thus, male recipients who received LT from female donors experienced 2.2 times increase in overall mortality as compared to male recipients who received livers from male donors (12% higher mortality at 5 years and 21% higher at 7 years post-LT).\u003c/p\u003e \u003cp\u003eNotably, neither weight nor height incompatibilities was related to inferior outcomes in this cohort. Thus, this is the first study showing that the deleterious association of female liver donors - male recipients is not related either to weight or to height incompatibility between donor and recipient.\u003c/p\u003e \u003cp\u003eThe few available literature studies on the subject exhibiting conflict results (\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10 CR11 CR12 CR13 CR14\" citationid=\"CR7\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e15\u003c/span\u003e). While some studies (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan additionalcitationids=\"CR14\" citationid=\"CR14\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e15\u003c/span\u003e) revealed that liver from female donors pose to an increased risk of death, other studies do not share the same results (\u003cspan additionalcitationids=\"CR9\" citationid=\"CR9\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e12\u003c/span\u003e). A recent systematic review and meta-analysis showed that female donors in male recipients was associated to an 83% decrease in post-LT survival (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e16\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eTo date, the reason for this inferior survival for male receiving livers from female donors has not been elucidated. Although some authors postulate that it may be related to different sizes among human males and females (a small-for-size effect) (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e16\u003c/span\u003e), the present study did not detect any association of weight and height mismatch to a decrease in overall post-LT survival. Moreover, even in the group of male recipients who received a liver from female donors, neither weight nor height differences accounted for any increase in mortality.\u003c/p\u003e \u003cp\u003eAs an attempt to elucidate the reasons for death of males receiving livers from female donors, a search for the reasons for graft failures was carried out. Interestingly, 58% of all first year mortality in this group was caused by infection. In contrast, infection was responsible for only 12.5% of all first year deaths of males who received livers from male donors.\u003c/p\u003e \u003cp\u003ePost-transplant infection was not a predictor of mortality in this study. However, infection was associated with a significant increase in post-transplant hospital stay. It is possible that greater rigor in immunosuppression could prevent the occurrence of infection in patients undergoing LT, positively impacting the long-term survival. The most common site for infection in our series was sepsis without a defined infectious site, with a total of 20 episodes (31.8%). The abdomen, the most common site of infection in literature studies, was only the third most common site of infection in the present study (20.6% of cases). These data differ in relation to two recent review articles, which establish the abdomen as the most common site of infection in LT recipients (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e18\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe present study has some limitations. The main one is the retrospective design. The nature of retrospective studies increases the chance of measurement biases. The absence of randomization is another limitation. However, it would be impossible to randomize LT patients to receive a liver graft from a specific deceased donor gender.\u003c/p\u003e \u003cp\u003eIn summary, female donor gender was associated to an increase in overall post-LT mortality, especially for male recipients. The reason for those inferior outcomes of male receiving livers from female donors was not related to anthropometric differences. For male patients receiving livers from female donors, infection was the most common cause of mortality occurring in the first year following LT. Thus, future studies are needed to elucidate whether immune discrepancies would be accountable for increased mortality of males receiving livers from female donors.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eALBI \u0026ndash; Albumin-Bilirubin score\u003c/p\u003e\n\u003cp\u003eAR \u0026ndash; Acute rejection during the first post-transplant year\u003c/p\u003e\n\u003cp\u003eHCC \u0026ndash; Hepatocellular carcinoma\u003c/p\u003e\n\u003cp\u003eMELD - Model for End-Stage Liver Disease\u003c/p\u003e\n\u003cp\u003eLT \u0026ndash; Liver Transplantation\u003c/p\u003e\n\u003cp\u003ePost-LT \u0026ndash; Post-Liver transplantation\u003c/p\u003e\n\u003cp\u003eHCV\u0026ndash; Hepatitis C virus\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eCOMPETING INTERESTS:\u0026nbsp;\u003c/strong\u003eThe authors have no conflicts of interest to disclose. This study was supported by the Hospital de Clinicas de Porto Alegre Research Incentive Fund (FIPE/HCPA, grant number 2017-0271).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRESEARCH INVOLVING HUMAN PARTICIPANTS (ETHICAL APPROVAL):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study complies with ethical standards and was approved by the Hospital de Cl\u0026iacute;nicas de Porto Alegre Institutional Review Board (\u003cem\u003eGrupo\u003c/em\u003e \u003cem\u003ede\u003c/em\u003e \u003cem\u003ePesquisa\u003c/em\u003e \u003cem\u003ee\u003c/em\u003e \u003cem\u003eP\u0026oacute;s-Gradua\u0026ccedil;\u0026atilde;o\u0026mdash;GPPG\u003c/em\u003e \u003cem\u003eHCPA\u003c/em\u003e). (2017-0271) All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was waived by the ethics committee because this is an observational retrospective study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAUTHOR\u0026rsquo;S CONTRIBUTIONS:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eM.F.C- Study conception and design, acquisition of data, analysis and interpretation of data, critical revision of manuscript.\u003c/p\u003e\n\u003cp\u003eL.P. - Study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript.\u003c/p\u003e\n\u003cp\u003eG.L.S - Analysis and interpretation of data, drafting of manuscript.\u003c/p\u003e\n\u003cp\u003eJ.C. - Acquisition of data, critical revision of manuscript.\u003c/p\u003e\n\u003cp\u003eN.Z. - Acquisition of data, critical revision of manuscript.\u003c/p\u003e\n\u003cp\u003eA.A. - Study conception and design, critical revision of manuscript.\u003c/p\u003e\n\u003cp\u003eR.M. - Study conception and design, critical revision of manuscript.\u003c/p\u003e\n\u003cp\u003eT.J.M.G.F - Study conception and design, critical revision of manuscript.\u003c/p\u003e\n\u003cp\u003eL.Z.G. - Study conception and design, analysis and interpretation of data, drafting of manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eRana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H, et al. No Gains in Long-Term Survival After Liver Transplantation Over the Past Three Decades. \u003cem\u003eAnn Surg\u003c/em\u003e. 2018.\u003c/li\u003e\n\u003cli\u003eAdam R, Sanchez C, Astarcioglu I, Bismuth H. (1995) Deleterious effect of extended cold ischemia time on the posttransplant outcome of aged livers. \u003cem\u003eTransplant Proc\u003c/em\u003e 27:1181-1183. \u003c/li\u003e\n\u003cli\u003eDeschenes M, Forbes C, Tchervenkov J, Barkun J, Metrakos P, Tector J, et al. (1999) Use of older donor livers is associated with more extensive ischemic damage on intraoperative biopsies during liver transplantation. \u003cem\u003eLiver Transpl Surg\u003c/em\u003e 5:357-361.\u003c/li\u003e\n\u003cli\u003eChedid MF, Rosen CB, Nyberg SL, Heimbach JK. Excellent long-term patient and graft survival are possible with the use of livers from deceased septuagenarian and octogenarian donors. \u003cem\u003eHPB (Oxford) \u003c/em\u003e2014; 16: 852-8.\u003c/li\u003e\n\u003cli\u003eBernardi N, Chedid MF, Grezzana-Filho TMJ, Chedid AD, Pinto MA, Leipnitz, et al. Pre-transplant ALBI grade 3 is associated with increased mortality after liver transplantation, \u003cem\u003eDig Dis Sci \u003c/em\u003e2019; 1695-1704.\u003c/li\u003e\n\u003cli\u003ePinto MA, Grezzana-Filho TJM, Chedid AD, Leipnitz I, Prediger JE, Alvares-da-Silva MR, de Ara\u0026uacute;jo A, Zahler S, Lopes BB, Giampaoli AZD, Kruel CRP, Chedid MF. Impact of intraoperative blood salvage and autologous transfusion during liver transplantation for hepatocellular carcinoma. \u003cem\u003eLangenbecks Arch Surg\u003c/em\u003e. 2021;406:67-74.\u003c/li\u003e\n\u003cli\u003eKahn D, Gavaler JS, Makowka L, van Thiel DH. Gender of donor influences outcome after orthotopic liver transplantation in adults\u003cem\u003e. Dig Dis Sci\u003c/em\u003e 1993; 38: 1485-1488.\u003c/li\u003e\n\u003cli\u003eMarino IR, Doyle HR, Aldrighetti L, Doria C, McMichael J, Gayowski T, Fung JJ, Tzakis AG, Starzl TE. Effect of donor age and sex on the outcome of liver transplantation. \u003cem\u003eHepatology\u003c/em\u003e 1995; 22: 1754-1762.\u003c/li\u003e\n\u003cli\u003eGrande L, Rull A, Rimola A, Manyalic M, Cabrer C, Garcia-Valdecasas JC, Navasa M, Fuster J, Lacy AM, Gonz\u0026aacute;lez FX, L\u0026oacute;pez-Boado MA, Visa J. Impact of donor gender on graft survival after liver transplantation. \u003cem\u003eTransplant Proc\u003c/em\u003e 1997; 29: 3373-3374.\u003c/li\u003e\n\u003cli\u003eBerrevoet F, Hesse UJ, de Laere S, Jacobs B, Pattyn P, de Hemptinne B. Impact of donor and recipient gender on liver transplantation. \u003cem\u003eTransplant Proc\u003c/em\u003e 1997; 29: 3431-3432.\u003c/li\u003e\n\u003cli\u003eBrooks BK, Levy MF, Jennings LW, Abbasoglu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Influence of donor and recipient gender on the outcome of liver transplantation. \u003cem\u003eTransplant Proc\u003c/em\u003e 1997; 29: 475-476.\u003c/li\u003e\n\u003cli\u003eCroome KP, Segal D, Hernandez-Alejandro R, Adams PC, Thomson A, Chandok N. Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants. \u003cem\u003eJ Hepatobiliary Pancreat Sci\u003c/em\u003e 2014; 21: 269-274.\u003c/li\u003e\n\u003cli\u003eGrąt M, Lewandowski Z, Patkowski W, Wronka KM, Grąt K, Krasnodębski M, Ligocka J, Zborowska H, Krawczyk M. Relevance of male-to-female sex mismatch in liver transplantation for primary biliary cirrhosis. \u003cem\u003eAnn Transplant\u003c/em\u003e 2015; 20: 116-123.\u003cbr\u003e \u003c/li\u003e\n\u003cli\u003eSchoening WN, Helbig M, Buescher N, Andreou A, Bahra M, Schmitz V, Pascher A, Pratschke J, Seehofer D. Gender Matches in Liver Transplant Allocation: Matched and Mismatched Male-Female Donor-Recipient Combinations; Long-term Follow-up of More Than 2000 Patients at a Single Center. Exp Clin Transplant. 2016 Apr;14(2):184-90. PMID: 27015533.\u003c/li\u003e\n\u003cli\u003eYoshizumi T, Shirabe K, Taketomi A, Uchiyama H, Harada N, Ijichi H, Yoshimatsu M, Ikegami T, Soejima Y, Maehara Y. Risk factors that increase mortality after living donor liver transplantation. Transplantation. 2012 Jan 15;93(1):93-8. doi: 10.1097/TP.0b013e318238dacd. PMID: 22203391.\u003c/li\u003e\n\u003cli\u003eLai JC, Feng S, Roberts JP, Terrault NA. Gender differences in liver donor quality are predictive of graft loss. Am J Transplant. 2011 Feb;11(2):296-302. doi: 10.1111/j.1600-6143.2010.03385.x. Epub 2011 Jan 10. PMID: 21219572; PMCID: PMC3076602.\u003c/li\u003e\n\u003cli\u003eLai Q, Giovanardi F, Melandro F, Larghi Laureiro Z, Merli M, Lattanzi B, Hassan R, Rossi M, Mennini G. Donor-to-recipient gender match in liver transplantation: A systematic review and meta-analysis. \u003cem\u003eWorld J Gastroenterol\u003c/em\u003e, 2018; 28;24(20):2203-2210.\u003c/li\u003e\n\u003cli\u003eGreen M. Introduction: Infections in solid organ transplantation. \u003cem\u003eAm J Transplant\u003c/em\u003e. 2013;13 Suppl 4:3-8. \u003c/li\u003e\n\u003cli\u003eKritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. \u003cem\u003eVirulence\u003c/em\u003e. 2016;7:329-40.\u003c/li\u003e\n\u003cli\u003eMaciel NB, Schwambach KH, Blatt CR. Liver Transplantation: Tacrolimus Blood Levels Variation and Survival, Rejection and Death Outcomes. Arq Gastroenterol.2021;58:370-376.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Liver transplantation, predictor, prognostic, survival, infection","lastPublishedDoi":"10.21203/rs.3.rs-4824616/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4824616/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eData on the influence donor gender on post-liver transplant outcomes is scarce / is lacking. The aim of this study was to evaluate the prognostic factors of mortality in patients undergoing liver transplantation (LT) with a thorough evaluation of the influence of the donor variables.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eRetrospective study of all patients undergoing LT at a single center from December 2011 to December 2018. The main outcome measure of the study was overall patient survival. The mortality predictors were evaluated using Cox regression.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eOverall, 202 patients analyzed in this study, 118 (58.1%) being males, and the average age was 54.19\u0026thinsp;\u0026plusmn;\u0026thinsp;11.66 years. Post-LT survival for the entire cohort of 202 patients as assessed by the Kaplan-Meier method at 1-, 3-, 5-, and 7 years was 81.6%, 73.1%, 67.6%, and 63%. The only predictor of increased overall mortality was female donor gender [HR\u0026thinsp;=\u0026thinsp;1.918, IC95%=1.150\u0026ndash;3.201, (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.013)]. Weight and height differences between donor and recipient were not related to mortality (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.545 for weight and \u003cem\u003ep\u0026thinsp;=\u003c/em\u003e\u0026thinsp;0.964 height).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eFemale donor gender was associated with an increase in overall post-LT mortality, especially for male recipients, regardless of anthropometric parameters. For male patients receiving livers from female donors, infection was the most common cause of mortality occurring in the first year following LT.\u003c/p\u003e","manuscriptTitle":"Female Donor Gender is Associated to a Decrease in Post-liver Transplant Survival of Male Recipients Independently to Donor and Recipient Anthropometric Differences","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-03 17:07:32","doi":"10.21203/rs.3.rs-4824616/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4646e6cc-a266-4039-b942-e009e842a17f","owner":[],"postedDate":"September 3rd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-09-03T17:07:34+00:00","versionOfRecord":[],"versionCreatedAt":"2024-09-03 17:07:32","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4824616","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4824616","identity":"rs-4824616","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}